Template:长效注射用抗精神病药物的药代动力学
外观
![]() | 根据维基百科删除方针,此模板已被提出存廢討論。請前往“頁面存廢討論”討論是否應該被刪除以協助達成共識。 |
药品 | 商品名 | 类型 | 溶剂 | 剂量 | 达峰时间 | 单次半衰期 | 多次半衰期 | 分配系数对数c | 参考 |
---|---|---|---|---|---|---|---|---|---|
Aripiprazole lauroxil | Aristada | 非典型 | 水a | 441–1064 mg/4–8星期 | 24–35日 | ? | 54–57日 | 7.9–10.0 | |
Aripiprazole monohydrate | Abilify Maintena | 非典型 | 水a | 300–400 mg/4星期 | 7日 | ? | 30–47日 | 4.9–5.2 | |
Bromperidol decanoate | Impromen Decanoas | 典型 | 芝麻油 | 40–300 mg/4星期 | 3–9日 | ? | 21–25日 | 7.9 | [1] |
Clopentixol decanoate | Sordinol Depot | 典型 | Viscoleob | 50–600 mg/1–4星期 | 4–7日 | ? | 19日 | 9.0 | [2] |
Flupentixol decanoate | Depixol | 典型 | Viscoleob | 10–200 mg/2–4星期 | 4–10日 | 8日 | 17日 | 7.2–9.2 | [2][3] |
Fluphenazine decanoate | Prolixin Decanoate | 典型 | 芝麻油 | 12.5–100 mg/2–5星期 | 1–2日 | 1–10日 | 14–100日 | 7.2–9.0 | [4][5][6] |
Fluphenazine enanthate | Prolixin Enanthate | 典型 | 芝麻油 | 12.5–100 mg/1–4星期 | 2–3日 | 4日 | ? | 6.4–7.4 | [5] |
Fluspirilene | Imap, Redeptin | 典型 | 水a | 2–12 mg/1星期 | 1–8日 | 7日 | ? | 5.2–5.8 | [7] |
Haloperidol decanoate | Haldol Decanoate | 典型 | 芝麻油 | 20–400 mg/2–4星期 | 3–9日 | 18–21日 | 7.2–7.9 | [8][9] | |
Olanzapine pamoate | Zyprexa Relprevv | 非典型 | 水a | 150–405 mg/2–4星期 | 7日 | ? | 30日 | – | |
Oxyprothepin decanoate | Meclopin | 典型 | ? | ? | ? | ? | ? | 8.5–8.7 | |
Paliperidone palmitate | Invega Sustenna | 非典型 | 水a | 39–819 mg/4–12星期 | 13–33日 | 25–139日 | ? | 8.1–10.1 | |
Perphenazine decanoate | Trilafon Dekanoat | 典型 | 芝麻油 | 50–200 mg/2–4星期 | ? | ? | 27日 | 8.9 | |
Perphenazine enanthate | Trilafon Enanthate | 典型 | 芝麻油 | 25–200 mg/2星期 | 2–3日 | ? | 4–7日 | 6.4–7.2 | [10] |
Pipotiazine palmitate | Piportil Longum | 典型 | Viscoleob | 25–400 mg/4星期 | 9–10日 | ? | 14–21日 | 8.5–11.6 | [3] |
Pipotiazine undecylenate | Piportil Medium | 典型 | 芝麻油 | 100–200 mg/2星期 | ? | ? | ? | 8.4 | |
Risperidone | Risperdal Consta | 非典型 | 微球 | 12.5–75 mg/2星期 | 21日 | ? | 3–6日 | – | |
Zuclopentixol acetate | Clopixol Acuphase | 典型 | Viscoleob | 50–200 mg/1–3星期 | 1–2日 | 1–2日 | 4.7–4.9 | ||
Zuclopentixol decanoate | Clopixol Depot | 典型 | Viscoleob | 50–800 mg/2–4星期 | 4–9日 | ? | 11–21日 | 7.5–9.0 | |
注释:全部为肌肉注射。脚注: a 微晶或纳米晶粒悬浊液。b 低黏度植物油(具体为含中链甘油三酯的椰子油)。c 来自于PubChem及DrugBank预测。主要来源:[11][12][13][14][15][16][17][18][19][20][21][22] |

参考文献
- ^ Parent M, Toussaint C, Gilson H. Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation.. Current Therapeutic Research. 1983, 34 (1): 1–6.
- ^ 2.0 2.1 Jørgensen A, Overø KF. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels. Acta Psychiatrica Scandinavica. Supplementum. 1980, 279: 41–54. PMID 6931472. doi:10.1111/j.1600-0447.1980.tb07082.x.
- ^ 3.0 3.1 Reynolds JE. Anxiolytic sedatives, hypnotics and neuroleptics.. Martindale: The Extra Pharmacopoeia 30th. London: Pharmaceutical Press. 1993: 364–623.
- ^ Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. The Journal of Clinical Psychiatry. May 1984, 45 (5 Pt 2): 50–9. PMID 6143748.
- ^ 5.0 5.1 Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA. Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. British Journal of Clinical Pharmacology. April 1979, 7 (4): 325–31. PMC 1429660
. PMID 444352. doi:10.1111/j.1365-2125.1979.tb00941.x.
- ^ Young D, Ereshefsky L, Saklad SR, Jann MW, Garcia N. Explaining the pharmacokinetics of fluphenazine through computer simulations. (Abstract.). 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists. Dallas, Texas. 1984.
- ^ Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, Marsboom RH, Hérin VV, Schaper WK. The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug. Arzneimittel-Forschung. November 1970, 20 (11): 1689–98. PMID 4992598.
- ^ Beresford R, Ward A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs. January 1987, 33 (1): 31–49. PMID 3545764. doi:10.2165/00003495-198733010-00002.
- ^ Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ. Pharmacokinetics of haloperidol decanoate. A 2-year follow-up. International Pharmacopsychiatry. 1982, 17 (4): 238–46. PMID 7185768. doi:10.1159/000468580.
- ^ Larsson M, Axelsson R, Forsman A. On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate.. Current Therapeutic Research. 1984, 36 (6): 1071–88.
- ^ Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. Depot antipsychotic drugs. Place in therapy. Drugs. May 1994, 47 (5): 741–73. PMID 7520856. doi:10.2165/00003495-199447050-00004.
- ^ Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clinical Pharmacokinetics. 1985, 10 (4): 315–33. PMID 2864156. doi:10.2165/00003088-198510040-00003.
- ^ Dencker SJ, Axelsson R. Optimising the Use of Depot Antipsychotics. CNS Drugs. 1996, 6 (5): 367–381. doi:10.2165/00023210-199606050-00004.
- ^ Lee LH, Choi C, Collier AC, Barr AM, Honer WG, Procyshyn RM. The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values. CNS Drugs. December 2015, 29 (12): 975–83. PMID 26585875. doi:10.1007/s40263-015-0295-2.
- ^ Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Current Clinical Pharmacology. 2014, 9 (3): 310–7. PMID 23343447. doi:10.2174/15748847113089990051.
- ^ Meyer JM. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectrums. December 2017, 22 (S1): 14–28. PMID 29350127. doi:10.1017/S1092852917000840.
- ^ Taylor D. Depot antipsychotics revisited. Psychiatric Bulletin. 2018, 23 (9): 551–553. ISSN 0955-6036. doi:10.1192/pb.23.9.551.
- ^ Stein G, Wilkinson G. Seminars in General Adult Psychiatry. RCPsych Publications. April 2007: 254–. ISBN 978-1-904671-44-2.
- ^ Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International Consensus Study of Antipsychotic Dosing. FOCUS. 2014, 12 (2): 235–243. ISSN 1541-4094. doi:10.1176/appi.focus.12.2.235.
- ^ Procyshyn RM, Bezchlibnyk-Butler KZ, Jeffries JJ. Clinical Handbook of Psychotropic Drugs. Hogrefe Verlag. 2019-05-15: 137–. ISBN 978-1-61676-561-3.
- ^ Kapfhammer HP. Umstellungsregime von Kurzzeit- auf Depotneuroleptika [Changeover regime from short-term to depot neuroleptics]. Thioxanthene in der Neuroleptischen Behandlung [Thioxanthenes in Neuroleptic Treatment]. 1990: 173–198. doi:10.1007/978-3-642-75194-3_18.
- ^ Wright JC, Burgess DJ. Long Acting Injections and Implants. Springer Science & Business Media. 2012-01-29: 114–117. ISBN 978-1-4614-0554-2.